Description: Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and other Tumors with Increased RET Activity.
Target Patient Population: Any advanced solid tumors, particularly those with known RET Gene alteration (NSCLC with RET fusions, Medullary thyroid cancer or other tumor types with RET alterations considered pathogenic)
Study Design: Drug is to be taken orally BID.